Low-Dose Adrenaline, Promethazine, and Hydrocortisone in the Prevention of Acute Adverse Reactions to Antivenom following Snakebite: A Randomised, Double-Blind, Placebo-Controlled Trial
Open Access
- 10 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 8 (5), e1000435
- https://doi.org/10.1371/journal.pmed.1000435
Abstract
Envenoming from snakebites is most effectively treated by antivenom. However, the antivenom available in South Asian countries commonly causes acute allergic reactions, anaphylactic reactions being particularly serious. We investigated whether adrenaline, promethazine, and hydrocortisone prevent such reactions in secondary referral hospitals in Sri Lanka by conducting a randomised, double-blind placebo-controlled trial. In total, 1,007 patients were randomized, using a 2×2×2 factorial design, in a double-blind, placebo-controlled trial of adrenaline (0.25 ml of a 1∶1,000 solution subcutaneously), promethazine (25 mg intravenously), and hydrocortisone (200 mg intravenously), each alone and in all possible combinations. The interventions, or matching placebo, were given immediately before infusion of antivenom. Patients were monitored for mild, moderate, or severe adverse reactions for at least 96 h. The prespecified primary end point was the effect of the interventions on the incidence of severe reactions up to and including 48 h after antivenom administration. In total, 752 (75%) patients had acute reactions to antivenom: 9% mild, 48% moderate, and 43% severe; 89% of the reactions occurred within 1 h; and 40% of all patients were given rescue medication (adrenaline, promethazine, and hydrocortisone) during the first hour. Compared with placebo, adrenaline significantly reduced severe reactions to antivenom by 43% (95% CI 25–67) at 1 h and by 38% (95% CI 26–49) up to and including 48 h after antivenom administration; hydrocortisone and promethazine did not. Adding hydrocortisone negated the benefit of adrenaline. Pretreatment with low-dose adrenaline was safe and reduced the risk of acute severe reactions to snake antivenom. This may be of particular importance in countries where adverse reactions to antivenom are common, although the need to improve the quality of available antivenom cannot be overemphasized. www.ClinicalTrials.gov NCT00270777 Please see later in the article for the Editors' SummaryKeywords
This publication has 22 references indexed in Scilit:
- Estimating the Global Burden of Snakebite Can Help To Improve ManagementPLoS Medicine, 2008
- The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and DeathsPLoS Medicine, 2008
- Antivenom use, premedication and early adverse reactions in the management of snake bites in rural Papua New GuineaToxicon, 2007
- Confronting the Neglected Problem of Snake Bite Envenoming: The Need for a Global PartnershipPLoS Medicine, 2006
- Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposiumJournal of Allergy and Clinical Immunology, 2006
- Clinical features and severity grading of anaphylaxisJournal of Allergy and Clinical Immunology, 2004
- Snake AntivenomsJournal of Toxicology: Clinical Toxicology, 2003
- A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenomsToxicon, 1999
- Fatal Intracranial Bleeding Associated With Prehospital Use of EpinephrineAnnals of Emergency Medicine, 1996
- Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites.BMJ, 1986